ArticleOncoimmunology2013
Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.Frontiers in immunology · 2023Review
- Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.Signal transduction and targeted therapy · 2022Review
- Molecular dissection of plasmacytoid dendritic cell activationThe EMBO journal · 2018Article
- Oncolytic viruses as engineering platforms for combination immunotherapy.Nature reviews. Cancer · 2018Review
- CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Oncoimmunology · 2016Article
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- Review
- Oncolytic virotherapy for human malignant mesothelioma: recent advances.Oncolytic virotherapy · 2015Review
- Review
- Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Frontiers in oncology · 2014Review
- Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.